BRAF and neoplasm: It is noted that the viral yields increased significantly in BRAF V600E-mutated tumor cells, about 8.6-fold for Widr cell and 6.7-fold for HT29 cell, respectively, when combination of oHSV and Trametinib at the concentration of 15 nM compared to oHSV alone at 72 hpi.